Results: Ninety-six (5.6%) of 1711 patients on AHOD0031 had LPHL. Patients with LPHL were more likely to achieve RER (93.6% vs. 81.0%; P = 0.002) and CR (74.2% vs. 49.3%; P = 0.000005) following chemotherapy compared with patients with classical HL. Five-year event-free survival (EFS) was superior in patients with LPHL (92.2%) versus classical HL (83.5%) (P = 0.04), without difference in overall survival (OS). Among RERs with CR following chemotherapy (n = 33), there was no difference in EFS or OS between those randomized to receive or not receive IFRT.
INTRODUCTION

Lymphocyte-predominant Hodgkin lymphoma (LPHL) is a variant of
Hodgkin lymphoma (HL) with distinct histopathology and clinical presentation. Although LPHL accounts for only 5% to 8% of all HL in adolescents between 15 and 20 years of age, it is more common in R-CHOP, Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; RER, Rapid early responder; SCFE, Société Française de lutte contre les Cancers et leucémies de l'Enfant et l'adolescent; SER, Slow early responder; SMN, subsequent malignant neoplasms prepubertal children, where it represents 10% to 20% of HL in that age group. [1] [2] [3] [4] Typically, LPHL presents with localized peripheral lymphadenopathy with only rare involvement of the mediastinum or extranodal sites. 5, 6 Pediatric patients with early-stage disease without bulk or B symptoms often have excellent outcomes with surgical resection alone or minimal chemotherapy. 7, 8 However, for pediatric patients with LPHL with unfavorable features such as higher stage disease, B symptoms, or bulk, management is less clear due to their small number in most intermediate-or high-risk HL clinical trials.
Risk-adapted HL therapy using chemotherapy response to guide treatment helps balance efficacy with toxicity. [9] [10] [11] [12] LPHL is the ideal group in which to leverage this paradigm. Children's Oncology Group (COG) AHOD0031 demonstrated that early response assessment in pediatric intermediate-risk HL permits reduction or augmentation in therapy with maintenance of excellent event-free (EFS) and overall survival (OS). 13 Patients with LPHL who met the same staging and eligibility criteria as patients with classical HL (cHL) were considered intermediate-risk and included in the study. Here, we report their outcomes and present directions for future therapeutic strategies.
PATIENTS AND METHODS
COG study AHOD0031, a randomized, response-based, centrally reviewed protocol approved by the National Cancer Institute and participating institutional review boards, enrolled patients from September 2002 through July 2009. 13 
Patients
Eligible patients included those younger than age 22 years with newly diagnosed, biopsy-proven cHL or LPHL, Ann Arbor 14 stages IB, IAE, IIB, IIAE, IIIA, IVA with or without bulk disease, and IA or IIA with bulk disease. Histology was centrally reviewed for eligibility. Bulk disease included a mediastinal mass greater than one third of the thoracic diameter on an upright anterior-posterior chest radiograph or extramediastinal nodal aggregate 6 cm in the longest transverse diameter on axial CT.
Treatment
Patients initially received two cycles of doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC), followed by a response evaluation of rapid early responder (RER) versus slow early responder (SER) status. Cycles were 21 days in duration. All SER patients were randomized to an additional two cycles of ABVE-PC with or without two cycles of dexamethasone, etoposide, cisplatin, and cytarabine (DECA), followed by 21 Gy involved field radiotherapy (IFRT) in 14 fractions of 1.5 Gy per day after completion of chemotherapy. RER patients received two additional cycles of ABVE-PC. Patients who were RERs with complete response (CR) following the total 4 cycles of chemotherapy were randomized to IFRT or no further therapy. RERs with less than CR were nonrandomly assigned to IFRT. IFRT was limited to areas of disease defined as involved at presentation.
Response criteria
Early response status was determined by CT scan, and CR status was Table 1) . The EFS and OS were calculated with Kaplan-Meier survival analysis, and the curves were compared between LPHL and non-LPHL groups with k-sample tests. For the LPHL patients, the EFS and OS curves were also compared across stage, between RER and SER, between IFRT and non-IFRT, between bulk and nonbulk, and between with B symptoms and without B symptoms. The EFS/OS curves were plotted for different levels of each factor (stage, RER/SER, bulk, or B symptoms), and k-sample test was performed to obtain the P value.
Statistical analysis
RESULTS
Patients and staging
Ninety-six of the 1711 eligible patients on AHOD0031 had LPHL (5.6%), with the remainder cHL ( Table 1) . Compared with patients with cHL, patients with LPHL were more likely to be younger (13.3 ± 3.6 vs.
14.6 ± 3.3, P = 0.0001) or male (P < 0.0001), and less likely to have B symptoms (P = 0.0012), bulk (P < 0.0001), or stage IV disease (P < 0.0001).
Therapy response
Of the 94 patients with LPHL with available data on early response (two patients were removed because their RER/SER status was unknown) there were 88 RERs and 6 SERs ( Figure 1 ). The proportion of patients who were RERs was higher in LPHL compared with cHL 
TA B L E 1 Study participants
Survival
Among patients with LPHL, for patients with cHL (P = 0.04) (Figure 2A ). The 5-year OS for the entire AHOD0031 cohort was excellent and did not differ for those with LPHL versus cHL; LPHL 98.9% (95% CI, 95.9% to 100%), cHL 97.3% (95% CI, 96.3% to 98.2%) (P = 0.20) (Figure 2B ). In LPHL, neither EFS or OS were impacted by stage of disease, bulk status, or B symptoms ( Table 2) .
Although early response was found to be an important prognostic factor for the AHOD0031 study cohort as a whole, 13 it was not found to significantly impact outcomes for patients with LPHL in this study.
Five-year EFS and OS was 92.7% (95% CI, 6.5% to 98.9%) and 98.8%
(95% CI, 96.2% to 100%), respectively, for LPHL RERs compared with 83.3% (95% CI, 36.1% to 100%) and 100% (95% CI, 100%) for LPHL SERs (P = 0.325 and P = 0.788) (Figure 3 ).
Similar to the findings from the analysis of all patients treated on AHOD0031, IFRT following 4 cycles of ABVE-PC did not improve outcome for the 61 patients with LPHL who were RER with CR and randomized to receive either IFRT (n = 28) or no IFRT (n = 33). Five-year EFS was 84.8% (95% CI, 69.5% to 100%) and OS was 96.3% (95% CI, 88.2% to 100%) for patients randomized to receive IFRT versus 93.4%
(95% CI, 84.3% to 100%) and 100% (95% CI, 100%) for those randomized to no IFRT (P = 0.287 and P = 0.284) (Figure 4 ). Outcomes did not apparently differ for the SER patients randomized to receive DECA (n = 5) or standard therapy (n = 1).
Events
There were eight relapses and one non-disease-related death among patients with LPHL. The median time to relapse for patients with LPHL (n = 8) was 1082.5 days (range, 83-3280 days) compared with 381 days (range, 54-4265) for patients with cHL (n = 244) (P < 0.0001). The one death was a trauma-related death that occurred after therapy completion as a first event in a patient who achieved an RER with CR and was randomized to receive IFRT. There were no subsequent malignant neoplasms (SMNs) in the patients with LPHL. Median follow-up for this group is 7.2 years (range, 1.1-13.5 years).
DISCUSSION
Patients with LPHL treated on regimens designed for cHL generally experience better outcomes than patients with cHL, 15 but may receive more treatment than is needed to achieve cure. Children and young adults with HL who are long-term survivors are at increased risk of late complications associated with chemotherapy and RT including SMNs, infertility, and cardiovascular disease. 16, 17 The ABVE-PC chemotherapy used in AHOD0031 was designed for dose-dense drug delivery to improve treatment efficacy while the response-based treatment design reduces total cumulative chemotherapy doses to reduce risk of long-term sequelae. 9 Although the included patients with LPHL met criteria for categorization as intermediate risk, in general, as has been reported elsewhere, 5 they had fewer risk factors including lower rates of B symptoms and bulk disease than the patients with cHL, and may benefit from different risk stratification than patients with cHL. Notably, the patients with LPHL had a much higher percentage of RERs compared with patients with cHL, suggesting that although they were treated on a response-based protocol, many of the patients with LPHL may have received more intensive chemotherapy than necessary because it was a protocol designed for cHL. In addition, the intensive treatment explains why EFS and OS were not affected by stage, bulk disease, or presence of B symptoms in patients with LPHL.
F I G U R E 3 (A) EFS and (B) OS for RER versus SER LP patients
F I G U R E 4 (A) EFS and (B) OS by IFRT random assignment for LP RER/CR patients
All patients with intermediate-risk HL received response-adapted therapy, and we identified a subgroup, RERs with CR, whose outcome was not significantly compromised by the exclusion of IFRT. 13 demonstrated that 75% of stage IA patients can avoid chemotherapy after complete surgical resection alone and >90% can avoid IFRT while maintaining excellent outcomes when treated with three cycles of doxorubicin, vincristine, prednisone, and cyclophosphamide (AV-PC). 8 The impact of low-dose IFRT on patients with LPHL was evaluated previously on study CCG-5942. 18 On this protocol, intermediate-risk commonly cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) (n = 5) or R-ABVD (n = 3). 21 Although numbers were small, the rituximab treatment group was notable for having a lower relapse rate of 8.3% (1/12) compared with the chemotherapy alone group rate of 15% (3/20) . Because the lymphocytic and histiocytic cells in LPHL consistently express CD20, rituximab, a chimeric anti-CD20 monoclonal antibody, may be an appropriate approach to consider in order to decrease exposure to cytotoxic chemotherapy. Growing experience using rituximab in young children has not found any obvious acute or long-term toxicity associated with B-cell depletion and has demonstrated efficacy in B-cell NHL. [22] [23] [24] Although LPHL in children and adults is not known to differ biologically, the treatment strategies for the two groups have differed.
The National Comprehensive Care Network (NCCN) guidelines (https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf) suggest CVP, ABVD, or CHOP with or without rituximab as the most common regimens for advanced-stage LPHL in adults. In adult studies of LPHL, rituximab has been used alone and in combination with other chemotherapy with promising results. [25] [26] [27] [28] Rituximab has been used as a single agent to treat 39 adult patients all of whom achieved a CR or PR after four weekly doses, with durable responses seen in patients treated with maintenance rituximab every 6 months for 2 years.
However, 23 of 39 patients experienced a relapse and 9 had evidence of transformation to aggressive B-cell NHL. 25 In a retrospective study of newly diagnosed adult patients with LPHL (n = 6), R-ABVD was efficacious with an estimated 6-year EFS and OS of 75% and 100% respectively. 26 Similarly, a retrospective analysis of 27 adult patients with advanced-stage LPHL demonstrated that R-CHOP was an effective treatment approach with an overall response rate of 100%
and a CR rate of 89%. 27 SMNs, in particular NHL, following a diagnosis of LPHL have been reported in both adult and pediatric series and could either represent a consequence of therapy or the natural history of LPHL. [29] [30] [31] Overall,
